---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046716"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:14:32.588989+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics reports FY2024 net loss $30M; going concern doubt, plans financing

## Summary
- FY2024 revenue $2.6M (vs $2.8M); net loss $30.0M (vs $25.0M); legal expenses $15.9M from arbitration.
- Q4 2024 revenue $394,804 (vs $1.3M); net loss $3.4M (vs $10.7M).
- Substantial doubt about going concern; financing plan includes $20M equity line with Square Gate and $7M milestone from WY Biotech license.
- Nasdaq extension to April 28 (bid price) and June 15 (other rules); special meeting March 31 for reverse split and conversions.
- IND cleared for HCW9302 Phase 1 in alopecia areata; Phase 2 ovarian cancer study closed due to poor enrollment.

## SEC filing metadata
- accession: 0000950170-25-046716
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025046716/0000950170-25-046716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025046716/hcwb-20250328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046716
- JSON: https://secwatch.observer/filing/0000950170-25-046716.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.